Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 Danish kroner ($58 ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

Future of Healthcategory· May 14, 2025 Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments Novo Nordisk has struck a collaboration and licensing deal with U.S ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

Some doubt has been cast on the future of pharma firm Novo Nordisk after its ousting... The FTSE 100 opened in the green on Tuesday as shares in Diploma Plc climbed 15 per... US drugmaker Pfizer said ...

Lars Fruergaard Jørgensen will step down as CEO of Novo Nordisk As Lars Fruergaard Jørgensen steps, Novo Nordisk seeks new leadership while production hurdles impact the competitive landscape After ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor ...

Novo Nordisk Pharma (Thailand) Ltd. is advancing its commitment to sustainable weight management among Thais through the launch of the “From My Weight to My Heart” campaign, aimed at reducing ...